Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 05 - 21 tags : Cancer save search
Modeling Data Showed Cologuard® Was Superior to Fecal Immunochemical Test (FIT) on Cost Effectiveness and Colorectal Cancer Incidence and Mortality
Published: 2021-05-21 (Crawled : 00:20) - biospace.com/
EXAS | $65.35 -10.42% -11.63% 3.1M
|
Health Technology
|
| O: 0.26%
H: 2.45%
C: 0.26%
test cancer colorectal cancer
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 23:00) - biospace.com/
GH | $17.06 -8.67% -9.5% 2.4M
|
Health Services
|
| O: 0.53%
H: 2.94%
C: 0.73%
fda lung cancer fda approval cancer approval diagnostic
Insights on the Breast Cancer Liquid Biopsy Global Market to 2027 - Opportunity Analysis and Industry Forecasts
Published: 2021-05-21 (Crawled : 22:00) - prnewswire.com
GH | $17.06 -8.67% -9.5% 2.4M
|
Health Services
| Email alert
Add to watchlist
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
| Email alert
Add to watchlist
cancer breast cancer
Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 20:00) - globenewswire.com
GMAB | $29.51 0.85% 0.85% 500K
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
fda lung cancer fda approval cancer ev growth approval
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 19:00) - prnewswire.com
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
treatment fda lung cancer fda approval cancer approval
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Published: 2021-05-21 (Crawled : 18:33) - fda.gov
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.22%
H: 0.97%
C: -0.65%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 0.36%
H: 1.01%
C: -0.28%
ADCT | $4.37 -0.46% 0.0% 460K
|
Health Technology
|
| O: 2.54%
H: 0.48%
C: -0.29%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.35%
H: 0.65%
C: -1.19%
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 0.58%
H: 1.24%
C: -1.66%
VSTM | $11.07 -2.04% -2.08% 120K
|
Health Technology
|
| O: 0.63%
H: 2.49%
C: -0.62%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
RIGL | $1.16 -3.33% -3.45% 770K
|
Health Technology
|
| O: 0.82%
H: 1.08%
C: -1.62%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.18%
H: 0.46%
C: -1.44%
KPTI | $1.155 -5.33% -5.63% 810K
|
Health Technology
|
| O: 0.31%
H: 1.15%
C: -1.46%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.57%
H: 0.6%
C: -1.46%
ILMN | $121.18 -4.64% -4.86% 1.6M
|
Health Technology
|
| O: 0.33%
H: 2.2%
C: 0.21%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: 0.08%
H: 1.64%
C: 0.45%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: -2.62%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.95%
H: 1.31%
C: -2.81%
BPMC | $85.19 -2.36% -2.42% 510K
|
Health Technology
|
| O: 1.12%
H: 0.84%
C: -0.08%
BGNE S | $138.39 -2.06% -2.1% 230K
|
Health Technology
|
| O: 0.1%
H: 1.6%
C: 0.88%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 1.19%
H: 1.71%
C: -0.33%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: 0.71%
H: 0.14%
C: -1.06%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.38%
H: 1.01%
C: -0.41%
AGIO | $29.29 -0.75% -0.75% 620K
|
Health Technology
|
| O: 0.86%
H: 1.27%
C: -0.24%
cancer approval
FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
Published: 2021-05-21 (Crawled : 18:33) - fda.gov
GH | $17.06 -8.67% -9.5% 2.4M
|
Health Services
| Email alert
Add to watchlist
fda cancer approval granted grant
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
Published: 2021-05-21 (Crawled : 17:00) - prnewswire.com
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.15%
H: 0.82%
C: -0.22%
fda lung cancer therapy cancer approval fda approval
Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
Published: 2021-05-21 (Crawled : 16:00) - biospace.com/
LNTH | $60.24 -0.91% -0.93% 650K
|
Health Technology
|
| O: 0.94%
H: 2.05%
C: 0.28%
presentation prostate cancer cancer imaging
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Published: 2021-05-21 (Crawled : 12:00) - biospace.com/
BGNE S | $138.39 -2.06% -2.1% 230K
|
Health Technology
|
| O: 0.1%
H: 1.6%
C: 0.88%
treatment positive therapy results cancer topline phase 3 trial
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.